Athero-Blocker – New peptides for the prevention and treatment of atherosclerosis
Scientists at the RWTH Aachen have identified new
peptides which can be used for the prevention of atherosclerosis or in the treatment of related cardiovascular diseases. It is known that adherent activated platelets secrete chemoattractants, such as the chemokines PF4 and RANTES, which are responsible for monocyterecruitment. Receptor-blocking experiments and studies with knock-out mice indicated that RANTES signals contribute to intimal hyperplasia and macrophage infiltration in models of restenosis. Moreover, it plays an important role in the initiation and maintenance of atherosclerosis. Athero-Blocker is specifically targeting the interaction between the chemokines RANTES and PF4. It can thereby abrogate the proatherogenic enhancement of monocyte recruitment caused by this interaction. A good efficacy of Athero-Blocker has been demonstrated in in vitro experiments, in cell based test systems and in mouse models in vivo.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Trotting robots reveal emergence of animal gait transitions
A four-legged robot trained with machine learning by EPFL researchers has learned to avoid falls by spontaneously switching between walking, trotting, and pronking – a milestone for roboticists as well…
Innovation promises to prevent power pole-top fires
Engineers in Australia have found a new way to make power-pole insulators resistant to fire and electrical sparking, promising to prevent dangerous pole-top fires and reduce blackouts. Pole-top fires pose…
Possible alternative to antibiotics produced by bacteria
Antibacterial substance from staphylococci discovered with new mechanism of action against natural competitors. Many bacteria produce substances to gain an advantage over competitors in their highly competitive natural environment. Researchers…
